Mechanisms underlying the influence of oestrogen on cardiovascular physiology in women

Journal of Physiology

Volumn 597, Issue 19, 2019, Pages 4873-4886

  Novella, Susana ^a   Pérez Cremades, Daniel ^a   Mompeón, Ana ^a   Hermenegildo, Carlos ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

endothelium; estrogen receptors; micro RNA

Indexed keywords

ANGIOTENSIN[1-7]; ESTROGEN; ESTROGEN RECEPTOR ALPHA; MICRORNA; NITRIC OXIDE; PROSTAGLANDIN SYNTHASE;

BINDING SITE; CARDIOVASCULAR FUNCTION; EPIGENETICS; ESTROGEN SYNTHESIS; FEMALE; HEART PROTECTION; HORMONAL REGULATION; HUMAN; INFLAMMATION; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ENDOTHELIUM, VASCULAR; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; HUMANS; MOLECULAR STRUCTURE; POSTMENOPAUSE;

EID: 85071342344     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/JP278063     Document Type: Review

References (140)

1. Addis R, Campesi I, Fois M, Capobianco G, Dessole S, Fenu G, Montella A, Cattaneo MG, Vicentini LM & Franconi F (2014). Human umbilical endothelial cells (HUVECs) have a sex: characterisation of the phenotype of male and female cells. Biol Sex Differ 5, 18.
2. Adler TE, Usselman CW, Takamata A & Stachenfeld NS (2018). Blood pressure predicts endothelial function and the effects of ethinyl estradiol exposure in young women. Am J Physiol Heart Circ Physiol 315, H925–H933.
3. Alvarez A, Hermenegildo C, Issekutz AC, Esplugues JV & Sanz MJ (2002). Estrogens inhibit angiotensin II-induced leukocyte-endothelial cell interactions in vivo via rapid endothelial nitric oxide synthase and cyclooxygenase activation. Circ Res 91, 1142–1150.
4. Arias-Loza PA, Hu K, Dienesch C, Mehlich AM, Konig S, Jazbutyte V, Neyses L, Hegele-Hartung C, Heinrich Fritzemeier K & Pelzer T (2007). Both estrogen receptor subtypes, α and β, attenuate cardiovascular remodeling in aldosterone salt-treated rats. Hypertension 50, 432–438.
5. 2 receptors. Am J Physiol Renal Physiol 283, F934–F943.
6. Arnal JF, Lenfant F, Metivier R, Flouriot G, Henrion D, Adlanmerini M, Fontaine C, Gourdy P, Chambon P, Katzenellenbogen B & Katzenellenbogen J (2017). Membrane and nuclear estrogen receptor α actions: from tissue specificity to medical implications. Physiol Rev 97, 1045–1087.
7. Bailey ST, Westerling T & Brown M (2015). Loss of estrogen-regulated microRNA expression increases HER2 signaling and is prognostic of poor outcome in luminal breast cancer. Cancer Res 75, 436–445.
8. Barton M (2013). Cholesterol and atherosclerosis: modulation by oestrogen. Curr Opin Lipidol 24, 214–220.
9. Bowling MR, Xing D, Kapadia A, Chen Y-F, Szalai AJ, Oparil S & Hage FG (2014). Estrogen effects on vascular inflammation are age dependent: Role of estrogen receptors. Arterioscler Thromb Vasc Biol 34, 1477–1485.
10. Brosnihan KB, Hodgin JB, Smithies O, Maeda N & Gallagher P (2008). Tissue-specific regulation of ACE/ACE2 and AT1/AT2 receptor gene expression by oestrogen in apolipoprotein E/oestrogen receptor-α knock-out mice. Exp Physiol 93, 658–664.
11. Brouchet L, Krust A, Dupont S, Chambon P, Bayard F & Arnal JF (2001). Estradiol accelerates reendothelialization in mouse carotid artery through estrogen receptor-α but not estrogen receptor-β. Circulation 103, 423–428.
12. Brown RD, Hilliard LM, Head GA, Jones ES, Widdop RE & Denton KM (2012). Sex differences in the pressor and tubuloglomerular feedback response to angiotensin II. Hypertension 59, 129–135.
13. Bukowska A, Spiller L, Wolke C, Lendeckel U, Weinert S, Hoffmann J, Bornfleth P, Kutschka I, Gardemann A, Isermann B & Goette A (2017). Protective regulation of the ACE2/ACE gene expression by estrogen in human atrial tissue from elderly men. Exp Biol Med (Maywood) 242, 1412–1423.
14. Burns KA & Korach KS (2012). Estrogen receptors and human disease: an update. Arch Toxicol 86, 1491–1504.
15. Cattaneo MG, Vanetti C, Decimo I, Di Chio M, Martano G, Garrone G, Bifari F & Vicentini LM (2017). Sex-specific eNOS activity and function in human endothelial cells. Sci Rep 7, 9612.
16. Cizeron-Clairac G, Lallemand F, Vacher S, Lidereau R, Bieche I & Callens C (2015). MiR-190b, the highest up-regulated miRNA in ERα-positive compared to ERα-negative breast tumors, a new biomarker in breast cancers? BMC Cancer 15, 499.
17. Clarkson TB, Melendez GC & Appt SE (2013). Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future. Menopause 20, 342–353.
18. 2+ entry mechanisms of coronary vasoconstriction. Arterioscler Thromb Vasc Biol 19, 1034–1040.
19. Csiszar A, Wang M, Lakatta EG & Ungvari Z (2008). Inflammation and endothelial dysfunction during aging: role of NF-κB. J Appl Physiol (1985) 105, 1333–1341.
20. Cutolo M, Capellino S, Sulli A, Serioli B, Secchi ME, Villaggio B & Straub RH (2006). Estrogens and autoimmune diseases. Ann N Y Acad Sci 1089, 538–547.
21. Chambliss KL & Shaul PW (2002). Estrogen modulation of endothelial nitric oxide synthase. Endocr Rev 23, 665–686.
22. Chen DB, Bird IM, Zheng J & Magness RR (2004). Membrane estrogen receptor-dependent extracellular signal-regulated kinase pathway mediates acute activation of endothelial nitric oxide synthase by estrogen in uterine artery endothelial cells. Endocrinology 145, 113–125.
23. Cheng C, Fu X, Alves P & Gerstein M (2009). mRNA expression profiles show differential regulatory effects of microRNAs between estrogen receptor-positive and estrogen receptor-negative breast cancer. Genome Biol 10, R90.
24. Dantas AP, Scivoletto R, Fortes ZB, Nigro D & Carvalho MH (1999). Influence of female sex hormones on endothelium-derived vasoconstrictor prostanoid generation in microvessels of spontaneously hypertensive rats. Hypertension 34, 914–919.
25. Dantas AP, Tostes RC, Fortes ZB, Costa SG, Nigro D & Carvalho MH (2002). In vivo evidence for antioxidant potential of estrogen in microvessels of female spontaneously hypertensive rats. Hypertension 39, 405–411.
26. David FL, Carvalho MH, Cobra AL, Nigro D, Fortes ZB, Reboucas NA & Tostes RC (2001). Ovarian hormones modulate endothelin-1 vascular reactivity and mRNA expression in DOCA-salt hypertensive rats. Hypertension 38, 692–696.
27. Davidge ST & Zhang Y (1998). Estrogen replacement suppresses a prostaglandin H synthase-dependent vasoconstrictor in rat mesenteric arteries. Circ Res 83, 388–395.
28. Dean SA, Tan J, O'Brien ER & Leenen FH (2005). 17β-Estradiol downregulates tissue angiotensin-converting enzyme and ANG II type 1 receptor in female rats. Am J Physiol Regul Integr Comp Physiol 288, R759–R766.
29. Deng L, Blanco FJ, Stevens H, Lu R, Caudrillier A, McBride M, McClure JD, Grant J, Thomas M, Frid M, Stenmark K, White K, Seto AG, Morrell NW, Bradshaw AC, MacLean MR & Baker AH (2015). MicroRNA-143 activation regulates smooth muscle and endothelial cell crosstalk in pulmonary arterial hypertension. Circ Res 117, 870–883.
30. Deroo BJ & Korach KS (2006). Estrogen receptors and human disease. J Clin Invest 116, 561–570.
31. Dubey RK, Jackson EK, Keller PJ, Imthurn B & Rosselli M (2001). Estradiol metabolites inhibit endothelin synthesis by an estrogen receptor-independent mechanism. Hypertension 37, 640–644.
32. Farhat MY, Lavigne MC & Ramwell PW (1996). The vascular protective effects of estrogen. FASEB J 10, 615–624.
33. Fichtlscherer S, Zeiher AM & Dimmeler S (2011). Circulating microRNAs: biomarkers or mediators of cardiovascular diseases? Arterioscler Thromb Vasc Biol 31, 2383–2390.
34. Fischer M, Baessler A & Schunkert H (2002). Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res 53, 672–677.
35. Förstermann U & Sessa WC (2012). Nitric oxide synthases: regulation and function. Eur Heart J 33, 829–837, 837a–837d.
36. 2+ uptake. Circ Res 81, 242–248.
37. Fredette NC, Meyer MR & Prossnitz ER (2018). Role of GPER in estrogen-dependent nitric oxide formation and vasodilation. J Steroid Biochem Mol Biol 176, 65–72.
38. Gallagher PE, Li P, Lenhart JR, Chappell MC & Brosnihan KB (1999). Estrogen regulation of angiotensin-converting enzyme mRNA. Hypertension 33, 323–328.
39. Gavin KM, Seals DR, Silver AE & Moreau KL (2009). Vascular endothelial estrogen receptor α is modulated by estrogen status and related to endothelial function and endothelial nitric oxide synthase in healthy women. Mol Endocrinol 23, 1307.
40. Gingerich S & Krukoff TL (2008). Activation of ERβ increases levels of phosphorylated nNOS and NO production through a Src/PI3K/Akt-dependent pathway in hypothalamic neurons. Neuropharmacology 55, 878–885.
41. Gupta A, Caffrey E, Callagy G & Gupta S (2012). Oestrogen-dependent regulation of miRNA biogenesis: many ways to skin the cat. Biochem Soc Trans 40, 752–758.
42. Harkonen PL & Vaananen HK (2006). Monocyte-macrophage system as a target for estrogen and selective estrogen receptor modulators. Ann N Y Acad Sci 1089, 218–227.
43. Haynes MP, Li L, Sinha D, Russell KS, Hisamoto K, Baron R, Collinge M, Sessa WC & Bender JR (2003). Src kinase mediates phosphatidylinositol 3-kinase/Akt-dependent rapid endothelial nitric-oxide synthase activation by estrogen. J Biol Chem 278, 2118–2123.
44. Haynes MP, Sinha D, Russell KS, Collinge M, Fulton D, Morales-Ruiz M, Sessa WC & Bender JR (2000). Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res 87, 677–682.
45. Hayward CS, Kelly RP & Collins P (2000). The roles of gender, the menopause and hormone replacement on cardiovascular function. Cardiovasc Res 46, 28–49.
46. Hermenegildo C, Lazaro-Franco M, Mompeon A, Perez-Cremades D, Vidal-Gomez X, Bueno-Beti C & Novella S (2013). Gender differences in nitric oxide production induced by estradiol in human endothelial cells. J Hypertens 31, e357.
47. Hilliard LM, Mirabito KM & Denton KM (2013a). Unmasking the potential of the angiotensin AT2 receptor as a therapeutic target in hypertension in men and women: what we know and what we still need to find out. Clin Exp Pharmacol Physiol 40, 542–550.
48. Hilliard LM, Sampson AK, Brown RD & Denton KM (2013b). The “his and hers” of the renin-angiotensin system. Curr Hypertens Rep 15, 71–79.
49. Hiroki J, Shimokawa H, Mukai Y, Ichiki T & Takeshita A (2005). Divergent effects of estrogen and nicotine on Rho-kinase expression in human coronary vascular smooth muscle cells. Biochem Biophys Res Commun 326, 154–159.
50. Huang ZP & Wang DZ (2014). miR-22 in cardiac remodeling and disease. Trends Cardiovasc Med 24, 267–272.
51. Hurtado R, Celani M & Geber S (2016). Effect of short-term estrogen therapy on endothelial function: a double-blinded, randomized, controlled trial. Climacteric 19, 448–451.
52. Huxley VH, Kemp SS, Schramm C, Sieveking S, Bingaman S, Yu Y, Zaniletti I, Stockard K & Wang J (2018). Sex differences influencing micro- and macrovascular endothelial phenotype in vitro. J Physiol 596, 3929–3949.
53. Ji H, Menini S, Zheng W, Pesce C, Wu X & Sandberg K (2008). Role of angiotensin-converting enzyme 2 and angiotensin(1-7) in 17β-oestradiol regulation of renal pathology in renal wrap hypertension in rats. Exp Physiol 93, 648–657.
54. Jiang CW, Sarrel PM, Lindsay DC, Poole-Wilson PA & Collins P (1991). Endothelium-independent relaxation of rabbit coronary artery by 17β-oestradiol in vitro. Br J Pharmacol 104, 1033–1037.
55. Jiang F, Yang J, Zhang Y, Dong M, Wang S, Zhang Q, Liu FF, Zhang K & Zhang C (2014). Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets. Nat Rev Cardiol 11, 413–426.
56. Joyner J, Neves LA, Granger JP, Alexander BT, Merrill DC, Chappell MC, Ferrario CM, Davis WP & Brosnihan KB (2007). Temporal-spatial expression of ANG-(1-7) and angiotensin-converting enzyme 2 in the kidney of normal and hypertensive pregnant rats. Am J Physiol Regul Integr Comp Physiol 293, R169–R177.
57. Kanashiro CA & Khalil RA (2001). Gender-related distinctions in protein kinase C activity in rat vascular smooth muscle. Am J Physiol Cell Physiol 280, C34–C45.
58. Khalil RA (2013). Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease. Biochem Pharmacol 86, 1627–1642.
59. Kim KH, Young BD & Bender JR (2014). Endothelial estrogen receptor isoforms and cardiovascular disease. Mol Cell Endocrinol 389, 65–70.
60. Kip KE, Marroquin OC, Shaw LJ, Arant CB, Wessel TR, Olson MB, Johnson BD, Mulukutla S, Sopko G, Merz CN & Reis SE (2005). Global inflammation predicts cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. Am Heart J 150, 900–906.
61. Kitazawa T, Hamada E, Kitazawa K & Gaznabi AK (1997). Non-genomic mechanism of 17β-oestradiol-induced inhibition of contraction in mammalian vascular smooth muscle. J Physiol 499, 497–511.
62. Klinge CM (2001). Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 29, 2905–2919.
63. Komukai K, Mochizuki S & Yoshimura M (2010). Gender and the renin-angiotensin-aldosterone system. Fundam Clin Pharmacol 24, 687–698.
64. Kondo T, Hirose M & Kageyama K (2009). Roles of oxidative stress and redox regulation in atherosclerosis. J Atheroscler Thromb 16, 532–538.
65. Kovats S (2015). Estrogen receptors regulate innate immune cells and signaling pathways. Cell Immunol 294, 63–69.
66. Lahm T, Crisostomo PR, Markel TA, Wang M, Wang Y, Tan J & Meldrum DR (2008). Selective estrogen receptor-α and estrogen receptor-β agonists rapidly decrease pulmonary artery vasoconstriction by a nitric oxide-dependent mechanism. Am J Physiol Regul Integr Comp Physiol 295, R1486–R1493.
67. Levin ER (2009). Plasma membrane estrogen receptors. Trends Endocrinol Metab 20, 477–482.
68. Lindberg MK, Moverare S, Skrtic S, Gao H, Dahlman-Wright K, Gustafsson JA & Ohlsson C (2003). Estrogen receptor (ER)-β reduces ERα-regulated gene transcription, supporting a “ying yang” relationship between ERα and ERβ in mice. Mol Endocrinol 17, 203–208.
69. Lobo RA (2017). Hormone-replacement therapy: current thinking. Nat Rev Endocrinol 13, 220–231.
70. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M; Women's Health Initiative Investigators (2003). Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349, 523–534.
71. i in mesenteric microvessels of female rat. J Pharmacol Exp Ther 352, 291.
72. Mendelsohn ME & Karas RH (1999). The protective effects of estrogen on the cardiovascular system. N Engl J Med 340, 1801–1811.
73. Mendelsohn ME & Karas RH (2005). Molecular and cellular basis of cardiovascular gender differences. Science 308, 1583–1587.
74. Meyer MR, Fredette NC, Barton M & Prossnitz ER (2015). G protein-coupled estrogen receptor inhibits vascular prostanoid production and activity. J Endocrinol 227, 61–69.
75. Meyer MR, Haas E, Prossnitz ER & Barton M (2009). Non-genomic regulation of vascular cell function and growth by estrogen. Mol Cell Endocrinol 308, 9–16.
76. Mikkola TS, Gissler M, Merikukka M, Tuomikoski P & Ylikorkala O (2013). Sex differences in age-related cardiovascular mortality. PLoS One 8, e63347.
77. Mompeón A, Lázaro-Franco M, Bueno-Betí C, Pérez-Cremades D, Vidal-Gómez X, Monsalve E, Gironacci MM, Hermenegildo C & Novella S (2016). Estradiol, acting through ERα, induces endothelial non-classic renin-angiotensin system increasing angiotensin 1–7 production. Mol Cell Endocrinol 422, 1–8.
78. Monsalve E, Oviedo PJ, Garcia-Perez MA, Tarin JJ, Cano A & Hermenegildo C (2007). Estradiol counteracts oxidized LDL-induced asymmetric dimethylarginine production by cultured human endothelial cells. Cardiovasc Res 73, 66–72.
79. Mori T, Durand J, Chen Y, Thompson JA, Bakir S & Oparil S (2000). Effects of short-term estrogen treatment on the neointimal response to balloon injury of rat carotid artery. Am J Cardiol 85, 1276–1279.
80. Mugge A, Riedel M, Barton M, Kuhn M & Lichtlen PR (1993). Endothelium independent relaxation of human coronary arteries by 17β-oestradiol in vitro. Cardiovasc Res 27, 1939–1942.
81. Murphy E & Steenbergen C (2014). Estrogen regulation of protein expression and signaling pathways in the heart. Biol Sex Differ 5, 6.
82. Najjar SS, Scuteri A & Lakatta EG (2005). Arterial aging: is it an immutable cardiovascular risk factor? Hypertension 46, 454–462.
83. Neves LA, Stovall K, Joyner J, Valdes G, Gallagher PE, Ferrario CM, Merrill DC & Brosnihan KB (2008). ACE2 and ANG-(1-7) in the rat uterus during early and late gestation. Am J Physiol Regul Integr Comp Physiol 294, R151–R161.
84. Nguyen Dinh Cat A & Touyz RM (2011). A new look at the renin–angiotensin system—Focusing on the vascular system. Peptides 32, 2141–2150.
85. Nickenig G, Baumer AT, Grohe C, Kahlert S, Strehlow K, Rosenkranz S, Stablein A, Beckers F, Smits JF, Daemen MJ, Vetter H & Bohm M (1998). Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation 97, 2197–2201.
86. Novella S, Heras M, Hermenegildo C & Dantas AP (2012). Effects of estrogen on vascular inflammation: a matter of timing. Arterioscler Thromb Vasc Biol 32, 2035–2042.
87. Novella S, Laguna-Fernandez A, Lazaro-Franco M, Sobrino A, Bueno-Beti C, Tarin JJ, Monsalve E, Sanchis J & Hermenegildo C (2013). Estradiol, acting through estrogen receptor α, restores dimethylarginine dimethylaminohydrolase activity and nitric oxide production in oxLDL-treated human arterial endothelial cells. Mol Cell Endocrinol 365, 11–16.
88. Novensa L, Novella S, Medina P, Segarra G, Castillo N, Heras M, Hermenegildo C & Dantas AP (2011). Aging negatively affects estrogens-mediated effects on nitric oxide bioavailability by shifting ERα/ERβ balance in female mice. PLoS One 6, e25335.
89. Ospina JA, Krause DN & Duckles SP (2002). 17β-Estradiol increases rat cerebrovascular prostacyclin synthesis by elevating cyclooxygenase-1 and prostacyclin synthase. Stroke 33, 600–605.
90. Pandey DP & Picard D (2009). miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor α mRNA. Mol Cell Biol 29, 3783–3790.
91. Hormone Therapy Position Statement Advisory Panel (2017). The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 24, 728–753.
92. Panic A, Stanimirovic J, Obradovic M, Zafirovic S, Sudar-Milovanovic E, Petrovic N & Isenovic ER (2018). 17β-Estradiol inhibits hepatic iNOS via the activation of the estrogen receptor ER-α and inhibition of ERK1/2-miR-221 axis. J Biol Regul Homeost Agents 32, 1369–1377.
93. Pare G, Krust A, Karas RH, Dupont S, Aronovitz M, Chambon P & Mendelsohn ME (2002). Estrogen receptor-α mediates the protective effects of estrogen against vascular injury. Circ Res 90, 1087–1092.
94. Pérez-Cremades D, Mompeón A, Vidal-Gomez X, Hermenegildo C & Novella S (2018a). Role of miRNA in the regulatory mechanisms of estrogens in cardiovascular ageing. Oxid Med Cell Longev 2018, 6082387.
95. Pérez-Cremades D, Mompeón A, Vidal-Gómez X, Hermenegildo C & Novella S (2018b). miRNA as a new regulatory mechanism of estrogen vascular action. Int J Mol Sci 19, 473.
96. Prossnitz ER & Barton M (2011). The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol 7, 715–726.
97. Queiros AM, Eschen C, Fliegner D, Kararigas G, Dworatzek E, Westphal C, Sanchez Ruderisch H & Regitz-Zagrosek V (2013). Sex- and estrogen-dependent regulation of a miRNA network in the healthy and hypertrophied heart. Int J Cardiol 169, 331–338.
98. Revankar CM, Cimino DF, Sklar LA, Arterburn JB & Prossnitz ER (2005). A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307, 1625–1630.
99. Rider V, Li X, Peterson G, Dawson J, Kimler BF & Abdou NI (2006). Differential expression of estrogen receptors in women with systemic lupus erythematosus. J Rheumatol 33, 1093–1101.
100. Rogers JL, Mitchell AR, Maric C, Sandberg K, Myers A & Mulroney SE (2007). Effect of sex hormones on renal estrogen and angiotensin type 1 receptors in female and male rats. Am J Physiol Regul Integr Comp Physiol 292, R794–R799.
101. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM & Ockene J (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321–333.
102. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL & Stefanick ML (2007). Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297, 1465–1477.
103. Rubio-Gayosso I, Sierra-Ramirez A, Garcia-Vazquez A, Martinez-Martinez A, Munoz-Garcia O, Morato T & Ceballos-Reyes G (2000). 17β-Estradiol increases intracellular calcium concentration through a short-term and nongenomic mechanism in rat vascular endothelium in culture. J Cardiovasc Pharmacol 36, 196–202.
104. Sampson AK, Moritz KM & Denton KM (2012). Postnatal ontogeny of angiotensin receptors and ACE2 in male and female rats. Gend Med 9, 21–32.
105. Sartoretto SM, Santos FF, Costa BP, Ceravolo GS, Santos-Eichler R, Carvalho MHC, Fortes ZB & Akamine EH (2019). Involvement of inducible nitric oxide synthase and estrogen receptor ESR2 (ERβ) in the vascular dysfunction in female type 1 diabetic rats. Life Sci 216, 279–286.
106. Seals DR, Jablonski KL & Donato AJ (2011). Aging and vascular endothelial function in humans. Clin Sci (Lond) 120, 357–375.
107. Shenoy V, Grobe JL, Qi Y, Ferreira AJ, Fraga-Silva RA, Collamat G, Bruce E & Katovich MJ (2009). 17β-Estradiol modulates local cardiac renin-angiotensin system to prevent cardiac remodeling in the DOCA-salt model of hypertension in rats. Peptides 30, 2309–2315.
108. Sherwood A, Bower JK, Fetridge-Durdle J, Blumenthal JA, Newby LK & Hinderliter AL (2007). Age moderates the short-term effects of transdermal 17β-estradiol on endothelium-dependent vascular function in postmenopausal women. Arterioscler Thromb Vasc Biol 27, 1782–1787.
109. Simoncini T, Rabkin E & Liao JK (2003). Molecular basis of cell membrane estrogen receptor interaction with phosphatidylinositol 3-kinase in endothelial cells. Arterioscler Thromb Vasc Biol 23, 198–203.
110. Singh T & Newman AB (2011). Inflammatory markers in population studies of aging. Ageing Res Rev 10, 319–329.
111. Sobrino A, Mata M, Laguna-Fernandez A, Novella S, Oviedo PJ, Garcia-Perez MA, Tarin JJ, Cano A & Hermenegildo C (2009). Estradiol stimulates vasodilatory and metabolic pathways in cultured human endothelial cells. PLoS One 4, e8242.
112. Sobrino A, Oviedo PJ, Novella S, Laguna-Fernandez A, Bueno C, Garcia-Perez MA, Tarin JJ, Cano A & Hermenegildo C (2010). Estradiol selectively stimulates endothelial prostacyclin production through estrogen receptor α. J Mol Endocrinol 44, 237–246.
113. Sobrino A, Vallejo S, Novella S, Lázaro-Franco M, Mompeón A, Bueno-Betí C, Walther T, Sánchez-Ferrer C, Peiró C & Hermenegildo C (2017). Mas receptor is involved in the estrogen-receptor induced nitric oxide-dependent vasorelaxation. Biochem Pharmacol 129, 67–72.
114. Sood R, Faubion SS, Kuhle CL, Thielen JM & Shuster LT (2014). Prescribing menopausal hormone therapy: an evidence-based approach. Int J Womens Health 6, 47–57.
115. Stanhewicz AE, Wenner MM & Stachenfeld NS (2018). Sex differences in endothelial function important to vascular health and overall cardiovascular disease risk across the lifespan. Am J Physiol Heart Circ Physiol 315, H1569–H1588.
116. Stork S, von Schacky C & Angerer P (2002). The effect of 17β-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled trial. Atherosclerosis 165, 301–307.
117. Straub RH (2007). The complex role of estrogens in inflammation. Endocr Rev 28, 521–574.
118. Su EJ, Lin ZH, Zeine R, Yin P, Reierstad S, Innes JE & Bulun SE (2009). Estrogen receptor-β mediates cyclooxygenase-2 expression and vascular prostanoid levels in human placental villous endothelial cells. Am J Obstet Gynecol 200, 427–427.
119. Sullivan JC (2008). Sex and the renin-angiotensin system: inequality between the sexes in response to RAS stimulation and inhibition. Am J Physiol Regul Integr Comp Physiol 294, R1220–R1226.
120. Sullivan JC, Rodriguez-Miguelez P, Zimmerman MA & Harris RA (2015). Differences in angiotensin (1-7) between men and women. Am J Physiol Heart Circ Physiol 308, H1171–H1176.
121. Sumi D & Ignarro LJ (2003). Estrogen-related receptor α1 up-regulates endothelial nitric oxide synthase expression. Proc Natl Acad Sci U S A 100, 14451–14456.
122. Suzuki A, Mizuno K, Ino Y, Okada M, Kikkawa F, Mizutani S & Tomoda Y (1996). Effects of 17β-estradiol and progesterone on growth-factor-induced proliferation and migration in human female aortic smooth muscle cells in vitro. Cardiovasc Res 32, 516–523.
123. Teoh H, Leung SW & Man RY (1999). Short-term exposure to physiological levels of 17β-estradiol enhances endothelium-independent relaxation in porcine coronary artery. Cardiovasc Res 42, 224–231.
124. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, Castoldi M, Soutschek J, Koteliansky V, Rosenwald A, Basson MA, Licht JD, Pena JT, Rouhanifard SH, Muckenthaler MU, Tuschl T, Martin GR, Bauersachs J & Engelhardt S (2008). MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456, 980–984.
125. Tsutsumi S, Zhang X, Takata K, Takahashi K, Karas RH, Kurachi H & Mendelsohn ME (2008). Differential regulation of the inducible nitric oxide synthase gene by estrogen receptors 1 and 2. J Endocrinol 199, 267–273.
126. Usselman CW, Stachenfeld NS & Bender JR (2016). The molecular actions of oestrogen in the regulation of vascular health. Exp Physiol 101, 356–361.
127. Valdes G, Germain AM, Corthorn J, Berrios C, Foradori AC, Ferrario CM & Brosnihan KB (2001). Urinary vasodilator and vasoconstrictor angiotensins during menstrual cycle, pregnancy, and lactation. Endocrine 16, 117–122.
128. Valverde MA, Rojas P, Amigo J, Cosmelli D, Orio P, Bahamonde MI, Mann GE, Vergara C & Latorre R (1999). Acute activation of Maxi-K channels (hSlo) by estradiol binding to the β subunit. Science 285, 1929–1931.
129. Vidal-Gómez X, Novella S, Pérez-Monzó I, Garabito M, Dantas AP, Segarra G, Hermenegildo C & Medina P (2016). Decreased bioavailability of nitric oxide in aorta from ovariectomized senescent mice. Role of cyclooxygenase. Exp Gerontol 76, 1–8.
130. Vidal-Gomez X, Perez-Cremades D, Mompeon A, Dantas AP, Novella S & Hermenegildo C (2018). MicroRNA as crucial regulators of gene expression in estradiol-treated human endothelial cells. Cell Physiol Biochem 45, 1878–1892.
131. Vrtacnik P, Ostanek B, Mencej-Bedrac S & Marc J (2014). The many faces of estrogen signaling. Biochem Med (Zagreb) 24, 329–342.
132. Wang F, He Q, Sun Y, Dai X & Yang XP (2010). Female adult mouse cardiomyocytes are protected against oxidative stress. Hypertension 55, 1172–1178.
133. Wang L, Tang ZP, Zhao W, Cong BH, Lu JQ, Tang XL, Li XH, Zhu XY & Ni X (2015). MiR-22/Sp-1 links estrogens with the up-regulation of cystathionine gamma-lyase in myocardium, which contributes to estrogenic cardioprotection against oxidative stress. Endocrinology 156, 2124–2137.
134. Wassmann S, Baumer AT, Strehlow K, van Eickels M, Grohe C, Ahlbory K, Rosen R, Bohm M & Nickenig G (2001). Endothelial dysfunction and oxidative stress during estrogen deficiency in spontaneously hypertensive rats. Circulation 103, 435–441.
135. + channels in human coronary artery smooth muscle cells. Cardiovasc Res 53, 650–661.
136. WHO (2016). The top 10 causes of death. Global Health Observatory Data. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
137. Xing D, Feng W, Miller AP, Weathington NM, Chen YF, Novak L, Blalock JE & Oparil S (2007). Estrogen modulates TNF-α-induced inflammatory responses in rat aortic smooth muscle cells through estrogen receptor-β activation. Am J Physiol Heart Circ Physiol 292, H2607–H2612.
138. Xing D, Nozell S, Chen YF, Hage F & Oparil S (2009). Estrogen and mechanisms of vascular protection. Arterioscler Thromb Vasc Biol 29, 289–295.
139. Zhan Y, Liu Z, Li M, Ding T, Zhang L, Lu Q, Liu X, Zhang Z, Vlessidis A, Aw TY, Liu Z & Yao D (2016). ERβ expression in the endothelium ameliorates ischemia/reperfusion-mediated oxidative burst and vascular injury. Free Radic Biol Med 96, 223–233.
140. Zhao J, Imbrie GA, Baur WE, Iyer LK, Aronovitz MJ, Kershaw TB, Haselmann GM, Lu Q & Karas RH (2013). Estrogen receptor-mediated regulation of microRNA inhibits proliferation of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 33, 257–265.